Shares of Bristol-Myers (BMY -0.7%) slide after a federal judge rules a U.S. patent for its hepatitis B treatment Baraclude is invalid, saying there's clear and convincing evidence that a key claim in the patent is invalid due to obviousness. The ruling opens the door to Teva Pharmaceutical (TEVA +0.4%) selling a competing generic copy. BMY says it's disappointed in the ruling and plans to appeal.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Feb 26, 2015)
at Benzinga.com (Feb 25, 2015)
at CNBC.com (Feb 17, 2015)
at Investor's Business Daily (Jan 27, 2015)
at CNBC.com (Jan 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs